Исследование аллергического отита у собак не доказывает, что лечение предотвращает рецидивы

Что учитывать: Исследование без нелеченой контрольной группы не устанавливает причинный эффект лечения. Результаты относятся к отобранной группе собак, продолжавших назначения после ремиссии при стабильном ведении аллергии, и не позволяют прогнозировать исход для конкретного животного.

В исследовании не было нелеченой контрольной группы, поэтому оно не доказывает, что именно поддерживающее лечение предотвратило рецидивы. Авторы описали исходы у собак, продолжавших назначенное лечение гидрокортизона ацепонатом после ремиссии при стабильном сопутствующем ведении аллергии.

На чём основано · 1

Исследование было ретроспективным многоцентровым наблюдением собак с аллергическим наружным отитом на поддерживающей терапии гидрокортизона ацепонатом в течение фиксированных 12 месяцев; единицей анализа была собака, а не отдельное ухо.

Граница вывода: Наблюдательный дизайн описывает исходы при назначенном лечении и сам по себе не устанавливает его причинный эффект.

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Точное место: Раздел 2.1 Study Design and Reporting, оба абзаца: ретроспективный многоцентровый наблюдательный дизайн и единица анализа.

Источник: Elisa Maina, Jasmine Chantale Rigert, Carlotta Filippini и др. Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study. Veterinary Medicine and Science, 2026. DOI: 10.1002/vms3.71276

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

This was a retrospective multicentre observational study of client‐owned dogs with allergic otitis externa receiving proactive topical hydrocortisone aceponate maintenance therapy over a fixed 12‐month observation period. The design and reporting were guided by STROBE recommendations for observational studies (von Elm et al. 2007). The unit of analysis was the dog. When both ears were affected, the dog was classified according to the more severe or clinically relevant otitis phenotype recorded before maintenance therapy.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Точное место: Раздел 3.1 Study Population, начало первого абзаца: исходная выборка, исключения, итоговая когорта, наблюдение и численность групп.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано · 2

Из медицинских записей 104 собак в итоговый анализ включили 71 собаку, а 33 исключили. Включение требовало клинической и цитологической ремиссии перед поддерживающей терапией, подтверждённого продолжения назначений, неизменного сопутствующего ведения аллергии и полных данных за 12 месяцев.

Граница вывода: Отбор ограничивает перенос результатов на всех собак, получивших первоначальное назначение. Полученные доли не являются индивидуальным прогнозом для конкретной собаки.

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Точное место: Раздел 2.2 Case Selection, второй абзац: ремиссия перед включением, подтверждение продолжения лечения, стабильность сопутствующего ведения аллергии и критерии исключения.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Only dogs for which treatment continuation was confirmed by owner telephone follow‐up and for which complete information for a fixed 12‐month observation period was available were included in the final analysis. Maintenance therapy was started only after clinical and cytological remission of the active otitis episode had been achieved. Concomitant allergy management, including systemic antipruritic or anti‐inflammatory treatment, allergen‐specific immunotherapy and diet, had to remain unchanged during the 12‐month observation period. Dogs were excluded if treatment had not been continued, if continuation could not be confirmed, if updated relapse information could not be obtained, or if follow‐up was shorter than 12 months. Dogs were also excluded if the maintenance schedule was changed, if hydrocortisone aceponate was not administered as prescribed, if concomitant allergy treatment or diet was initiated, discontinued or changed during follow‐up, or if complete 12‐month outcome data were not available.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано · 3

В исследовании не было нелеченой контрольной группы, поэтому оно не доказывает, что именно поддерживающая терапия гидрокортизона ацепонатом обусловила наблюдаемую частоту рецидивов. Лёгкие или недостаточно документированные эпизоды могли быть пропущены, а соблюдение назначений оценивали по сообщениям владельцев без объективного измерения.

Граница вывода: По этим данным нельзя вычислить индивидуальную вероятность рецидива, доказать преимущество перед отсутствием лечения или определить время наступления рецидива у конкретной собаки.

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Точное место: Раздел 4 Discussion, последний абзац перед разделом 5 Conclusion: определение рецидива, пропущенные эпизоды, неизвестные даты, оценка соблюдения назначений и отсутствие нелеченой контрольной группы.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Кого и как наблюдали

Это ретроспективное многоцентровое наблюдательное исследование: авторы анализировали медицинские записи и уточняли сведения у владельцев по телефону. Из первоначальных 104 собак в итоговый анализ включили 71, а 33 исключили. Каждую включённую собаку наблюдали 12 месяцев; единицей анализа была собака, а не отдельное ухо.

На чём основано · 1

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

This was a retrospective multicentre observational study of client‐owned dogs with allergic otitis externa receiving proactive topical hydrocortisone aceponate maintenance therapy over a fixed 12‐month observation period. The design and reporting were guided by STROBE recommendations for observational studies (von Elm et al. 2007). The unit of analysis was the dog. When both ears were affected, the dog was classified according to the more severe or clinically relevant otitis phenotype recorded before maintenance therapy.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано · 2

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Only dogs for which treatment continuation was confirmed by owner telephone follow‐up and for which complete information for a fixed 12‐month observation period was available were included in the final analysis. Maintenance therapy was started only after clinical and cytological remission of the active otitis episode had been achieved. Concomitant allergy management, including systemic antipruritic or anti‐inflammatory treatment, allergen‐specific immunotherapy and diet, had to remain unchanged during the 12‐month observation period. Dogs were excluded if treatment had not been continued, if continuation could not be confirmed, if updated relapse information could not be obtained, or if follow‐up was shorter than 12 months. Dogs were also excluded if the maintenance schedule was changed, if hydrocortisone aceponate was not administered as prescribed, if concomitant allergy treatment or diet was initiated, discontinued or changed during follow‐up, or if complete 12‐month outcome data were not available.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Поддерживающее лечение начинали после клинической и цитологической ремиссии. Для включения требовались подтверждённое продолжение назначенного лечения, неизменное сопутствующее ведение аллергии и полные сведения об исходе. Поэтому итоговая выборка описывает собак, продолжавших назначения, а не всех животных, которым первоначально назначили препарат.

На чём основано

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Only dogs for which treatment continuation was confirmed by owner telephone follow‐up and for which complete information for a fixed 12‐month observation period was available were included in the final analysis. Maintenance therapy was started only after clinical and cytological remission of the active otitis episode had been achieved. Concomitant allergy management, including systemic antipruritic or anti‐inflammatory treatment, allergen‐specific immunotherapy and diet, had to remain unchanged during the 12‐month observation period. Dogs were excluded if treatment had not been continued, if continuation could not be confirmed, if updated relapse information could not be obtained, or if follow‐up was shorter than 12 months. Dogs were also excluded if the maintenance schedule was changed, if hydrocortisone aceponate was not administered as prescribed, if concomitant allergy treatment or diet was initiated, discontinued or changed during follow‐up, or if complete 12‐month outcome data were not available.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Что зарегистрировали за время наблюдения

Исходы за 12 месяцев в итоговой когорте; доверительные интервалы — 95%-е.
Исход	Число собак	Доля	Доверительный интервал доли
Без зарегистрированных рецидивов	50 из 71	70,4%	58,4–80,7%
Один рецидив	12 из 71	16,9%	9,0–27,7%
Несколько рецидивов	9 из 71	12,7%	6,0–22,7%

На чём основано

За 12 месяцев у 50 из 71 собаки не зарегистрировали рецидивов аллергического наружного отита; у 21 собаки был хотя бы один рецидив. Рецидивом считали эпизод, потребовавший ветеринарного осмотра, цитологического подтверждения и дополнительного лечения уха.

Граница вывода: Это наблюдаемые исходы отобранной когорты. Возможны пропуски эпизодов, не соответствовавших условиям регистрации или не попавших в документацию.

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Точное место: Раздел 3.3 Overall Relapse Outcome, абзац перед таблицей 3: распределение рецидивов за 12 месяцев, доверительные интервалы и суммарное число эпизодов.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Over the 12‐month observation period, 50/71 dogs (70.4%; 95% CI, 58.4–80.7%) had no relapse and 21/71 dogs (29.6%; 95% CI, 19.3–41.6%) had at least one relapse. Twelve dogs (16.9%; 95% CI, 9.0–27.7%) had one relapse, whereas nine dogs (12.7%; 95% CI, 6.0–22.7%) had multiple relapses. Overall relapse outcomes and comparisons between protocols are summarised in Table 3. The total relapse count was 39 over 71 dog‐years, corresponding to 0.55 relapses/dog‐year.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Хотя бы один рецидив зарегистрировали у 21 из 71 собаки: 29,6%, 95%-й доверительный интервал 19,3–41,6%. Эта группа объединяет собак с одним и несколькими рецидивами.

На чём основано

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Over the 12‐month observation period, 50/71 dogs (70.4%; 95% CI, 58.4–80.7%) had no relapse and 21/71 dogs (29.6%; 95% CI, 19.3–41.6%) had at least one relapse. Twelve dogs (16.9%; 95% CI, 9.0–27.7%) had one relapse, whereas nine dogs (12.7%; 95% CI, 6.0–22.7%) had multiple relapses. Overall relapse outcomes and comparisons between protocols are summarised in Table 3. The total relapse count was 39 over 71 dog‐years, corresponding to 0.55 relapses/dog‐year.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Рецидивом считали эпизод, потребовавший ветеринарного осмотра, цитологического подтверждения и дополнительного лечения уха. Поэтому «без зарегистрированного рецидива» не означает «без любых симптомов»: лёгкие эпизоды без осмотра могли остаться неучтёнными.

На чём основано · 1

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Over the 12‐month observation period, 50/71 dogs (70.4%; 95% CI, 58.4–80.7%) had no relapse and 21/71 dogs (29.6%; 95% CI, 19.3–41.6%) had at least one relapse. Twelve dogs (16.9%; 95% CI, 9.0–27.7%) had one relapse, whereas nine dogs (12.7%; 95% CI, 6.0–22.7%) had multiple relapses. Overall relapse outcomes and comparisons between protocols are summarised in Table 3. The total relapse count was 39 over 71 dog‐years, corresponding to 0.55 relapses/dog‐year.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано · 2

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Статистически значимого различия между сравнивавшимися вариантами поддерживающего лечения не обнаружили. Сам по себе этот результат не доказывает, что варианты одинаково эффективны.

На чём основано

Хотя бы один рецидив зарегистрировали у 9 из 36 собак в первой группе и у 12 из 35 во второй; статистически значимого различия по этому исходу не обнаружили.

Граница вывода: Отсутствие статистически значимого различия само по себе не доказывает одинаковую эффективность. Результат наблюдательного сравнения не позволяет самостоятельно выбирать или менять назначения.

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

This was a retrospective multicentre observational study of client‐owned dogs with allergic otitis externa receiving proactive topical hydrocortisone aceponate maintenance therapy over a fixed 12‐month observation period. The design and reporting were guided by STROBE recommendations for observational studies (von Elm et al. 2007). The unit of analysis was the dog. When both ears were affected, the dog was classified according to the more severe or clinically relevant otitis phenotype recorded before maintenance therapy.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Точное место: Раздел 3.4 Comparison Between Maintenance Protocols, первые два предложения: хотя бы один рецидив в группах, относительный риск, доверительный интервал и p.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

At least one relapse occurred in 9/36 dogs (25.0%; 95% CI, 12.1–42.2%) receiving Protocol 1 and in 12/35 dogs (34.3%; 95% CI, 19.1–52.2%) receiving Protocol 2. This difference was not statistically significant (relative risk for Protocol 2 compared with Protocol 1, 1.37; 95% CI, 0.66–2.84; p = 0.443).

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Что ограничивает выводы

Без нелеченой контрольной группы нельзя определить, какую часть наблюдаемого результата обеспечил препарат.
Отбор исключил собак, прекративших лечение, неправильно использовавших препарат, изменивших назначения или сопутствующее ведение аллергии, а также не имевших полных данных. Их исходы итоговая доля не отражает.
Сопутствующее ведение аллергии оставалось стабильным, но не было рандомизировано или стандартизировано; его влияние на результат исключить нельзя.
Соблюдение назначений подтверждали со слов владельцев без объективного измерения. Лечение в другом месте при неполной документации могло быть пропущено.
Из-за неполных сведений о датах не анализировали время до первого рецидива.

На чём основано · 1

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Only dogs for which treatment continuation was confirmed by owner telephone follow‐up and for which complete information for a fixed 12‐month observation period was available were included in the final analysis. Maintenance therapy was started only after clinical and cytological remission of the active otitis episode had been achieved. Concomitant allergy management, including systemic antipruritic or anti‐inflammatory treatment, allergen‐specific immunotherapy and diet, had to remain unchanged during the 12‐month observation period. Dogs were excluded if treatment had not been continued, if continuation could not be confirmed, if updated relapse information could not be obtained, or if follow‐up was shorter than 12 months. Dogs were also excluded if the maintenance schedule was changed, if hydrocortisone aceponate was not administered as prescribed, if concomitant allergy treatment or diet was initiated, discontinued or changed during follow‐up, or if complete 12‐month outcome data were not available.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано · 2

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Что обсудить на приёме

Достигнута ли клиническая и цитологическая ремиссия и какова цель поддерживающего назначения после неё.
Как действовать при возвращении симптомов и когда повторно оценивать состояние уха.
Какие затруднения возникли с выполнением назначений и менялось ли другое лечение аллергии.

На чём основано · 1

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Only dogs for which treatment continuation was confirmed by owner telephone follow‐up and for which complete information for a fixed 12‐month observation period was available were included in the final analysis. Maintenance therapy was started only after clinical and cytological remission of the active otitis episode had been achieved. Concomitant allergy management, including systemic antipruritic or anti‐inflammatory treatment, allergen‐specific immunotherapy and diet, had to remain unchanged during the 12‐month observation period. Dogs were excluded if treatment had not been continued, if continuation could not be confirmed, if updated relapse information could not be obtained, or if follow‐up was shorter than 12 months. Dogs were also excluded if the maintenance schedule was changed, if hydrocortisone aceponate was not administered as prescribed, if concomitant allergy treatment or diet was initiated, discontinued or changed during follow‐up, or if complete 12‐month outcome data were not available.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано · 2

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Over the 12‐month observation period, 50/71 dogs (70.4%; 95% CI, 58.4–80.7%) had no relapse and 21/71 dogs (29.6%; 95% CI, 19.3–41.6%) had at least one relapse. Twelve dogs (16.9%; 95% CI, 9.0–27.7%) had one relapse, whereas nine dogs (12.7%; 95% CI, 6.0–22.7%) had multiple relapses. Overall relapse outcomes and comparisons between protocols are summarised in Table 3. The total relapse count was 39 over 71 dog‐years, corresponding to 0.55 relapses/dog‐year.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано · 3

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Препарат, дозу и схему лечения назначает ветеринарный врач. Результаты этой работы не позволяют самостоятельно выбрать назначение или рассчитать вероятность рецидива для своей собаки.

На чём основано

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано · 1

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

This was a retrospective multicentre observational study of client‐owned dogs with allergic otitis externa receiving proactive topical hydrocortisone aceponate maintenance therapy over a fixed 12‐month observation period. The design and reporting were guided by STROBE recommendations for observational studies (von Elm et al. 2007). The unit of analysis was the dog. When both ears were affected, the dog was classified according to the more severe or clinically relevant otitis phenotype recorded before maintenance therapy.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано · 2

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Only dogs for which treatment continuation was confirmed by owner telephone follow‐up and for which complete information for a fixed 12‐month observation period was available were included in the final analysis. Maintenance therapy was started only after clinical and cytological remission of the active otitis episode had been achieved. Concomitant allergy management, including systemic antipruritic or anti‐inflammatory treatment, allergen‐specific immunotherapy and diet, had to remain unchanged during the 12‐month observation period. Dogs were excluded if treatment had not been continued, if continuation could not be confirmed, if updated relapse information could not be obtained, or if follow‐up was shorter than 12 months. Dogs were also excluded if the maintenance schedule was changed, if hydrocortisone aceponate was not administered as prescribed, if concomitant allergy treatment or diet was initiated, discontinued or changed during follow‐up, or if complete 12‐month outcome data were not available.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Over the 12‐month observation period, 50/71 dogs (70.4%; 95% CI, 58.4–80.7%) had no relapse and 21/71 dogs (29.6%; 95% CI, 19.3–41.6%) had at least one relapse. Twelve dogs (16.9%; 95% CI, 9.0–27.7%) had one relapse, whereas nine dogs (12.7%; 95% CI, 6.0–22.7%) had multiple relapses. Overall relapse outcomes and comparisons between protocols are summarised in Table 3. The total relapse count was 39 over 71 dog‐years, corresponding to 0.55 relapses/dog‐year.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

This was a retrospective multicentre observational study of client‐owned dogs with allergic otitis externa receiving proactive topical hydrocortisone aceponate maintenance therapy over a fixed 12‐month observation period. The design and reporting were guided by STROBE recommendations for observational studies (von Elm et al. 2007). The unit of analysis was the dog. When both ears were affected, the dog was classified according to the more severe or clinically relevant otitis phenotype recorded before maintenance therapy.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

At least one relapse occurred in 9/36 dogs (25.0%; 95% CI, 12.1–42.2%) receiving Protocol 1 and in 12/35 dogs (34.3%; 95% CI, 19.1–52.2%) receiving Protocol 2. This difference was not statistically significant (relative risk for Protocol 2 compared with Protocol 1, 1.37; 95% CI, 0.66–2.84; p = 0.443).

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

На чём основано

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Medical records of 104 dogs prescribed hydrocortisone aceponate ear spray for proactive management of allergic otitis externa were screened. Seventy‐one dogs met the final inclusion criteria. Thirty‐three dogs were excluded because treatment was not started or not continued for the required period, the maintenance schedule or concomitant allergy management changed, owner follow‐up could not confirm the required information, or complete 12‐month outcome data were not available. All dogs received hydrocortisone aceponate ear spray. All included dogs had 12 months of follow‐up, and continuation of the prescribed maintenance protocol was confirmed by owner telephone follow‐up. Thirty‐six dogs received Protocol 1 and 35 dogs received Protocol 2.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.

Условия использования: Creative Commons Attribution (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/ Лицензия источника

Relapse was defined more strictly than owner‐reported recurrence alone, requiring veterinary examination, otic cytology and additional otic treatment. However, retrospective relapse assessment remains vulnerable to recall and recording bias. Minor episodes managed by owners without veterinary examination, or episodes treated elsewhere without complete documentation, may have been missed. Exact dates of relapse were not consistently available, so time‐to‐first‐relapse analysis could not be performed. This limitation is partly mitigated by the fixed 12‐month observation period, which allowed relapse frequency and relapse rate per dog‐year to be compared between groups, but it prevents comparison of relapse timing. Adherence was confirmed by owner report but was not objectively measured. Finally, the study had no untreated control group; therefore, it cannot prove that hydrocortisone aceponate maintenance therapy caused the low relapse frequency, only that relapse frequency was low in dogs that continued the intended regimen under stable management conditions.

Связь с утверждением: подтверждает · полный текст · DOI 10.1002/vms3.71276 · опубликован 1 ноября 2026

Редакция Породотеки

Об этом материале

Кому и где применимо: Разбор относится к собакам с аллергическим наружным отитом, получавшим поддерживающее лечение гидрокортизона ацепонатом после клинической и цитологической ремиссии. В итоговую когорту вошли только животные с подтверждённым продолжением назначений, стабильным сопутствующим ведением аллергии и полными данными наблюдения. Результаты нельзя автоматически переносить на всех собак с отитом или на лечение активного эпизода.

Проверка и история

Опубликовано: 27 октября 2026
Проверено: 27 октября 2026
Финансирование: Отдельная оценка финансирования в этот разбор не включена.
Конфликт интересов: Отдельная оценка конфликтов интересов в этот разбор не включена.

Постоянный адрес материала.

27 октября 2026 · Опубликована версия

Сообщить об ошибке